Read more about the article Entera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6

Entera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6

Continue ReadingEntera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6
Read more about the article Vonetize Plc: Agreements signed with content providers expand operations to the US, LATAM, Africa, CIS and Europe; purchase of controlling interest by Desilu Studios Inc. materially confirms market potential for its product; target price raised to NIS 1.85

Vonetize Plc: Agreements signed with content providers expand operations to the US, LATAM, Africa, CIS and Europe; purchase of controlling interest by Desilu Studios Inc. materially confirms market potential for its product; target price raised to NIS 1.85

Continue ReadingVonetize Plc: Agreements signed with content providers expand operations to the US, LATAM, Africa, CIS and Europe; purchase of controlling interest by Desilu Studios Inc. materially confirms market potential for its product; target price raised to NIS 1.85
Read more about the article Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85

Continue ReadingKadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85
Read more about the article Enlight Renewable Energy Ltd.: Purchase price/Kw for major project at Emek HaBacha conditional approved by the Electricity Authority; approved Growth in revenues from sales of electricity in Q1-2018; full commercial operation in Ireland and Croatia; progress made on wind farm in Kosovo; stock target price increased to 2.41.

Enlight Renewable Energy Ltd.: Purchase price/Kw for major project at Emek HaBacha conditional approved by the Electricity Authority; approved Growth in revenues from sales of electricity in Q1-2018; full commercial operation in Ireland and Croatia; progress made on wind farm in Kosovo; stock target price increased to 2.41.

Enlight Renewable Energy Ltd. is an Israeli company founded in 2008, and is publically traded on the Tel Aviv Stock Exchange. The company specializes in the initiation, development, financing, construction,…

Continue ReadingEnlight Renewable Energy Ltd.: Purchase price/Kw for major project at Emek HaBacha conditional approved by the Electricity Authority; approved Growth in revenues from sales of electricity in Q1-2018; full commercial operation in Ireland and Croatia; progress made on wind farm in Kosovo; stock target price increased to 2.41.
Read more about the article Energix: Polish Power Exchange reforms have a positive effect; stake in Ilawa Wind Energy project in Poland increased from 75% to 100%; all projects in development are progressing according to schedule; target price raised to NIS 4.61

Energix: Polish Power Exchange reforms have a positive effect; stake in Ilawa Wind Energy project in Poland increased from 75% to 100%; all projects in development are progressing according to schedule; target price raised to NIS 4.61

Continue ReadingEnergix: Polish Power Exchange reforms have a positive effect; stake in Ilawa Wind Energy project in Poland increased from 75% to 100%; all projects in development are progressing according to schedule; target price raised to NIS 4.61
Read more about the article Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.

Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.

Continue ReadingEntera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.
Read more about the article DNA Biomedical Solutions Ltd. Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre-IND (505(b)(2) submission; Target price remains unchanged.

DNA Biomedical Solutions Ltd. Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre-IND (505(b)(2) submission; Target price remains unchanged.

Continue ReadingDNA Biomedical Solutions Ltd. Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre-IND (505(b)(2) submission; Target price remains unchanged.
Read more about the article Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018, without the need for further capital raising; target price unchanged.

Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018, without the need for further capital raising; target price unchanged.

Continue ReadingBrainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018, without the need for further capital raising; target price unchanged.